3 year follow-up of the CheckMate 9ER trial: NIVO + cabozantinib vs sunitinib for first-line treatment of aRCC

Nivolumab and salvage nivolumab plus ipilimumab for aRCC

Cabozantinib in combination w/ nivolumab and ipilimumab of IMDC intermediate or poor risk significantly improved PFS vs PBO

Lenvatinib plus pembro for aRCC - update on the CLEAR study

CheckMate 9ER: aRCC patients on nivolumab plus cabozantinib achieved deeper responses vs sunitinib

Update: Cabozantinib plus nivolumab demonstrates continued survival benefit in aRCC

Biomarker analysis from JAVELIN Renal 101: Avelumab plus axitinib versus sunitinib in aRCC